Blog
Studying Molecular Systems With Digital High-throughput SPR
BlogSpeaking to Technology Networks, Ryan Denomme highlights the key challenges faced when using “traditional” surface plasmon resonance (SPR), how SPR is being used to aid drug discoveries, and explains the benefits of designing an SPR instrument that integrates digital microfluidics, artificial intelligence, and nanotechnology.
Read More
Yeast, A "Rising" Approach to Manufacturing Collagen
BlogTechnology Networks spoke with Jonathan Widdowson, Director of ProColl and Enterprise Fellow at the Royal Academy of Engineering Enterprise Hub, to learn more about how yeast can be used to manufacture collagens and the applications of this approach.
The Power of Positrons
BlogOver the last five to ten years, multi-modal imaging has become established as a significant component of a preclinical researcher’s analytical toolbox. Here, we highlight perhaps the most used and certainly the most sensitive and quantitative of these imaging modalities, the combination of positron emission tomography (PET) with X-ray computed tomography (CT), or PET/CT.
Read More
Driving Medical Innovation To Improve the Lives of Patients
BlogTechnology Networks recently spoke with LifeArc’s CEO Melanie Lee, PhD, CBE. Melanie elaborates on LifeArc's mission, discusses the importance of bridging the gap between "bench" and "bedside", and highlights how genomics can help drive earlier intervention.
Drug Candidate for Lung Cancer Receives FDA Fast Track Designation
BlogTechnology Networks spoke with Rodney Varner, CEO of Genprex, to learn more about the next steps for Oncoprex, a lead drug candidate that treats non-small cell lung cancer, and how the FDA Fast Track Designation will facilitate the delivery of this drug to cancer patients.
Read More
Leveraging AI To Find the “Right” Clinical Trial
BlogLess than 5% of adult cancer patients enroll in clinical trials even though it is estimated that a large percentage (70% of Americans) are very willing to take part in a clinical study. So, why is there such a large discrepancy in the number of actual participants versus those willing to, but not actually participating?
Read More
Exploring the Therapeutic Potential of Psychedelics
BlogTechnology Networks recently interviewed Ronan Levy, Founder and Executive Chairman of Field Trip Psychedelics, Inc. to find out more about the therapeutic potential of psychedelics and hear about the drugs undergoing clinical investigation.
Read More
A New Generation of Recombinant Monoclonal Antibodies
BlogTechnology Networks spoke with Isaku Tanida, Head of Protein and Pathway Technologies, Life Science at Merck to learn about Merck's ZooMAb® recombinant antibodies. These antibodies are developed from a B-cell immortalization technology which enables production in a variety of species.
Read More
Addressing the Need for an Effective Anticoagulant
BlogTechnology Networks recently spoke with Dr Neil Hayward Ph.D., CEO at eXIthera Pharmaceuticals to learn more about the role of the intrinsic and extrinsic pathways, and how they are exploiting coagulation mechanisms to develop antithrombotic therapeutics.
Read More
Drugging the Microbiome To Treat Obesity
BlogTechnology Networks recently spoke with Paul-Peter Tak, President & CEO, Kintai Therapeutics, to learn more about the anti-obesity agent the company is currently developing.
Read More
